References
1 Schug SA. Opioids: Clinical use.
In: McMahon SB et al (eds) Wall
& Melzack’s Textbook of Pain. 6th
edn. Amsterdam: Elsevier; 2013.
2 Pert CB, Snyder SH. Opiate
receptor: demonstration
in nervous tissue. Science
1973;179:1011–14.
3 Hughes J et al. Identification
of two related pentapeptides
from the brain with potent
opioid agonist activity. Nature
1975;258:577–80.
4 Macintyre PE, Loadsman JA,
Scott DA. Opioids, ventilation and
acute pain management. Anaesth
Intensive Care 2011;39(4):545–58.
5 Bannister K. Opioid-induced
hyperalgesia: where are we now?
Curr Opin Support Palliat Care
2015;9(2):116–21.
6 O’Rourke TK Jr, Wosnitzer
MS. Opioid-Induced Androgen
Deficiency (OPIAD): Diagnosis,
management, and literature
review. Curr Urol Rep
2016;17(10):76.
7 Ninkovic J, Roy S. Role of the
mu-opioid receptor in opioid
modulation of immune function.
Amino Acids 2013;45(1):9–24.
8 Wiese AD et al. Opioid
analgesic use and risk for
invasive pneumococcal diseases:
A nested case-control study. Ann
Intern Med 2018;168(6):396–404.
9 Vowles KE et al. Rates of opioid
misuse, abuse, and addiction
in chronic pain: a systematic
review and data synthesis. Pain
2015;156(4):569–76.
10 Lee J et al. Population
pharmacokinetic
analysis of tramadol
and O-desmethyltramadol
with genetic polymorphism
of CYP2D6. Drug Des Devel Ther
2019;13:1751–61.
11 Raffa RB et al. Opioid
and nonopioid components
independently contribute to
the mechanism of action of
tramadol, an ‘atypical’ opioid
analgesic. J Pharmacol Exp Ther
1992;260(1):275–85.
12 Raffa RB. On subclasses of
opioid analgesics. Curr Med Res
Opin 2014;30(12):2579–84.
13 Desmeules JA et al.
Contribution of monoaminergic
modulation to the analgesic
effect of tramadol. Br J Clin
Pharmacol 1996;41(1):7–12.
14 Grond S, Sablotzki A. Clinical
pharmacology of tramadol. Clin
Pharmacokinet 2004;43(13):
879–923.
15 Raffa RB, Friderichs E.
The basic science aspect of
tramadol hydrochloride. Pain Rev
1996;3:249–71.
16 Murphy JD et al. Comparison
of the postoperative analgesic
efficacy of intravenous patientcontrolled
analgesia with
tramadol to intravenous patientcontrolled
analgesia with opioids.
J Opioid Manage 2010;6(2):141–7.
17 Leppert W. Tramadol as an
analgesic for mild to moderate
cancer pain. Pharmacol Rep
2009;61(6):978–92.
18 Rosenberg MT. The role of
tramadol ER in the treatment
of chronic pain. Int J Clin Pract
2009;63(10):1531–43.
19 Cepeda MS et al. Tramadol
for osteoarthritis: a systematic
review and metaanalysis. J
Rheumatol 2007;34(3):543–55.
20 Duehmke RM et al. Tramadol
for neuropathic pain in adults.
Cochrane Database Syst Rev
2017;6:CD003726.
21 Tarkkila P, Tuominen M,
Lindgren L. Comparison of
respiratory effects of tramadol
and oxycodone. J Clin Anesth
1997;9(7):582–5.
22 Tarkkila P, Tuominen M,
Lindgren L. Comparison of
respiratory effects of tramadol
and pethidine. Eur J Anaesthesiol
1998;15(1):64–8.
23 Mildh LH, Leino KA, Kirvela
OA. Effects of tramadol and
meperidine on respiration,
plasma catecholamine
concentrations, and
hemodynamics. J Clin Anesth
1999;11(4):310–16.
24 Warren PM et al. Influence
of tramadol on the ventilatory
response to hypoxia in humans.
Br J Anaesth 2000;85(2):211–16.
25 Hassanian-Moghaddam H et
al. Tramadol-induced apnea. Am
J Emerg Med 2013;31(1):26–31.
26 Tsai YC, Won SJ. Effects
of tramadol on T lymphocyte
proliferation and natural
killer cell activity in rats with
sciatic constriction injury. Pain
2001;92(1-2):63–9.
27 Sacerdote P et al. The effects
of tramadol and morphine on
immune responses and pain
after surgery in cancer patients.
Anesth Analg 2000;90(6):
1411–14.
28 Sansone RA, Sansone LA.
Tramadol: seizures, serotonin
syndrome, and coadministered
antidepressants. Psychiatry
(Edgmont) 2009;6(4):17–21.
29 Hassamal S et al. Tramadol:
Understanding the risk of
serotonin syndrome and seizures.
Am J Med 2018;131(11):1382.
e1-1382.e6.
30 Miotto K et al. Trends in
tramadol: Pharmacology,
metabolism, and misuse. Anesth
Analg 2017;124(1):44–51.
31 Brouquet A et al. Impaired
mobility, ASA status and
administration of tramadol are
risk factors for postoperative
delirium in patients aged 75
years or more after major
abdominal surgery. Ann Surg
2010;251(4):759–65.
32 Somogyi AA, Barratt DT,
Coller JK. Pharmacogenetics
of opioids. Clin Pharmacol Ther
2007;81(3):429–44.
33 Fliegert F, Kurth B, Gohler
K. The effects of tramadol
on static and dynamic
pupillometry in healthy
subjects--the relationship
between pharmacodynamics,
pharmacokinetics and CYP2D6
metaboliser status. Eur J Clin
Pharmacol 2005;61(4):257–66.
34 Stamer UM et al. Impact
of CYP2D6 genotype on
postoperative tramadol
analgesia. Pain 2003;105
(1-2):231–8.
35 Stamer UM et al. Respiratory
depression with tramadol in a
patient with renal impairment
and CYP2D6 gene duplication.
Anesth Analg 2008;107(3):926–9.
36 Faria J et al. Comparative
pharmacology and toxicology of
tramadol and tapentadol. Eur
J Pain 2018;22(5):827–44.
37 Gressler LE, Hammond DA,
Painter JT. Serotonin syndrome in
tapentadol literature: Systematic
review of original research. J
Pain Palliat Care Pharmacother
2017;31(3-4):228–36.
38 Tzschentke TM, Christoph T,
Kogel BY. The mu-opioid receptor
agonist/noradrenaline reuptake
inhibition (MOR-NRI) concept in
analgesia: the case of tapentadol.
CNS Drugs 2014;28(4):319–29.
39 Christoph T et al. Spinalsupraspinal
and intrinsic
mu-opioid receptor agonistnorepinephrine
reuptake inhibitor
(MOR-NRI) synergy of tapentadol
in diabetic heat hyperalgesia
in mice. J Pharmacol Exp Ther
2013;347(3):794–801.
40 Niesters M et al. Tapentadol
potentiates descending pain
inhibition in chronic pain patients
with diabetic polyneuropathy. Br
J Anaesth 2014;113(1):148–56.
41 Lange B et al. Efficacy and
safety of tapentadol prolonged
release for chronic osteoarthritis
pain and low back pain. Adv Ther
2010;27(6):381–99.
42 Wiffen PJ et al. Oral
tapentadol for cancer pain.
Cochrane Database Syst Rev
2015;9:CD011460.
43 Vinik AI et al. A randomized
withdrawal, placebo-controlled
study evaluating the efficacy
and tolerability of tapentadol
extended release in patients
with chronic painful diabetic
peripheral neuropathy. Diabetes
Care 2014;37(8):2302–09.
44 Xiao JP et al. Efficacy and
safety of tapentadol immediate
release assessment in treatment
of moderate to severe pain:
A systematic review and metaanalysis.
Pain Med 2017;18(1):
14–24.
45 Sánchez del Águila M et al.
Practical considerations for the
use of tapentadol prolonged
release for the management of
severe chronic pain. Clin Ther
2015;37:94–113.
46 van der Schrier R et al. An
experimental study comparing
the respiratory effects of
tapentadol and oxycodone in
healthy volunteers. Br J Anaesth
2017;119(6):1169–77.
47 Baron R et al. Tolerability,
safety, and quality of life with
tapentadol prolonged release
(PR) compared with oxycodone/
naloxone PR in patients with
severe chronic low back pain
with a neuropathic component:
A randomized, controlled, openlabel,
Phase 3b/4 trial. Pain Pract
2016;16(5):600–19.
48 Meng Z et al. Tolerability of
opioid analgesia for chronic pain:
A network meta-analysis. Sci Rep
2017;7(1):1995.
49 Franchi S et al. Effect of
tapentadol on splenic cytokine
production in mice. Anesth Analg
2017;124(3):986–95.
50 Cowan A. Buprenorphine: the
basic pharmacology revisited.
J Addict Med 2007;1(2):68–72.
51 Khanna IK, Pillarisetti S.
Buprenorphine – an attractive
opioid with underutilized
potential in treatment of chronic
pain. J Pain Res 2015;8:859–70.
52 Kress HG. Clinical update
on the pharmacology, efficacy
and safety of transdermal
buprenorphine. Eur J Pain
2009;13(3):219–30.
53 Davis MP. Twelve reasons
for considering buprenorphine
as a frontline analgesic in the
management of pain. J Support
Oncol 2012;10(6):209–19.
54 Cote J, Montgomery L.
Sublingual buprenorphine as
an analgesic in chronic pain:
a systematic review. Pain Med
2014;15(7):1171–8.
55 Li X, Shorter D, Kosten TR.
Buprenorphine in the treatment
of opioid addiction: opportunities,
challenges and strategies.
Expert Opin Pharmacother
2014;15(15):2263–75.
56 Vlok R et al. Sublingual
buprenorphine versus
intravenous or intramuscular
morphine in acute pain:
A systematic review and
meta-analysis of randomized
control trials. Am J Emerg Med
2019;37(3):381–6.
57 Evans HC, Easthope SE.
Transdermal buprenorphine.
Drugs 2003;63(19):1999–2010;
discussion 1–2.
58 Dahan A et al. Comparison
of the respiratory effects of
intravenous buprenorphine and
fentanyl in humans and rats. Br
J Anaesth 2005;94(6):825–34.
59 Dahan A et al. Buprenorphine
induces ceiling in respiratory
depression but not in analgesia.
Br J Anaesth 2006;96(5):627–32.
60 Selden T et al. Toxicological
and pathological findings in a
series of buprenorphine related
deaths. Possible risk factors for
fatal outcome. Forensic Sci Int
2012;220(1-3):284–90.
61 Coplan PM et al. Comparison
of abuse, suspected suicidal
intent, and fatalities related
to the 7-day buprenorphine
transdermal patch versus other
opioid analgesics in the National
Poison Data System. Postgrad
Med 2017;129(1):55–61.
62 Sittl R, Nuijten M, Nautrup BP.
Changes in the prescribed daily
doses of transdermal fentanyl
and transdermal buprenorphine
during treatment of patients
with cancer and noncancer
pain in Germany: results of
a retrospective cohort study.
Clin Ther 2005;27(7):1022–31.
63 Koppert W et al. Different
profiles of buprenorphineinduced
analgesia and
antihyperalgesia in a human pain
model. Pain 2005;118(1-2):15–22.
64 Mercieri M et al. Lowdose
buprenorphine infusion
to prevent postoperative
hyperalgesia in patients
undergoing major lung surgery
and remifentanil infusion:
a double-blind, randomized,
active-controlled trial. Br
J Anaesth 2017;119(4):792–802.
65 Watkins LR et al. The “toll” of
opioid-induced glial activation:
improving the clinical efficacy of
opioids by targeting glia. Trends
Pharmacol Sci 2009;30(11):
581–91.
66 Van Loveren H et al.
Assessment of immunotoxicity
of buprenorphine. Lab Anim
1994;28(4):355–63.
67 Gomez-Flores R, Weber
RJ. Differential effects of
buprenorphine and morphine
on immune and neuroendocrine
functions following acute
administration in the rat
mesencephalon periaqueductal
gray. Immunopharmacology
2000;48(2):145–56.
68 Bliesener N et al. Plasma
testosterone and sexual function
in men receiving buprenorphine
maintenance for opioid
dependence. J Clin Endocrinol
Metab 2005;90(1):203–6.
69 Vestergaard P, Rejnmark
L, Mosekilde L. Fracture risk
associated with the use of
morphine and opiates. J Intern
Med 2006;260(1):76–87.
70 Lavonas EJ et al. Abuse and
diversion of buprenorphine
sublingual tablets and film.
J Subst Abuse Treat 2014;47(1):
27–34.
71 Raffa RB, Elling C, Tzschentke
TM. Does ‘strong analgesic’ equal
‘strong opioid’? Tapentadol and
the concept of ‘mu-load’. Adv
Ther 2018;35(10):1471–84.
10 | 2020 | hospitalpharmacyeurope.com